Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) revealed a profit for its full year that Increased, from the same period last year
The company's bottom line came in at RMB651.504 million, or RMB0.58 per share. This compares with RMB601.569 million, or RMB0.54 per share, last year.
The company's revenue for the period rose 8.5% to RMB4.352 billion from RMB4.012 billion last year.
Shenzhen Salubris Pharmaceuticals Co., Ltd. earnings at a glance (GAAP) :
-Earnings: RMB651.504 Mln. vs. RMB601.569 Mln. last year.-EPS: RMB0.58 vs. RMB0.54 last year.-Revenue: RMB4.352 Bln vs. RMB4.012 Bln last year.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.